WestVac Biopharma/Sichuan University West China Medical Center’s recombinant multivalent COVID-19 protein vaccine against XBB mutant has been approved for clinical trial by China State Drug Administration.

Chengdu, China, May 18, 2023 /CNW/ — ON May 17, 2023a recombinant bivalent COVID-19 protein vaccine (Sf9 cells) and a recombinant trivalent COVID-19 trimeric protein vaccine (Sf9 cells) developed by WestVac Biopharma/West China Medical Center, Sichuan The university recently obtained a “Pharmaceutical Clinical Trial Approval” from the National Drug Administration for a circulating XBB variant. China. These two new vaccines will soon be commercialized for protection against the currently circulating XBB variant of his, once the necessary clinical trials have been completed. These two vaccines are also the world’s first COVID-19 vaccines to initiate clinical trials specifically for mutant strains like XBB.

The Joint Prevention and Control Mechanism of the State Council held a press conference early in the morning. May 2023. In a meeting, as inbound and outbound interactions, China and other countries, the global impact on the composition of the major pandemic variants of COVID-19 in our country has increased dramatically.According to monitoring data[1]major pandemic variants of the novel coronavirus disease (COVID-19) virus China It has evolved into the XBB series. In this context, WestVac Biopharma is using its international advanced insect cell recombinant protein vaccine platform to develop a recombinant bivalent COVID-19 (XBB + prototype strain) protein vaccine (Sf9 cells) Coviccine® Develop valent and recombinant trivalent COVID-19 (XBB+BA). 5 + delta variant) trimeric protein vaccine (Sf9 cells). WestVac’s two vaccines are essential in the prevention of his current XBB variant and will greatly contribute to the ongoing management of the COVID-19 outbreak..

Coviccine® Bivalent — Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 cells)

The recombinant COVID-19 bivalent (XBB+prototype) protein vaccine (Sf9 cells) is an upgraded version of the Coviccine® — recombinant COVID-19 vaccine (Sf9 cells) developed by WestVac Biopharma. Studies show that the vaccine produced high titers of neutralizing antibodies against multiple subvariants including his XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.5, BF.7, BQ.1 has been shown to induce[1]This indicates that this vaccine is a universal novel coronavirus vaccine that is effective against multiple strains, with a particularly notable increase in neutralizing antibodies against the XBB series mutants.

Recombinant COVID-19 trivalent (XBB+BA.5+delta) trimeric protein vaccine (Sf9 cells)

Utilizing the rapid response of an internationally advanced insect cell expression platform in recombinant protein vaccine production, WestVac Biopharma and its subsidiary WestVac Biopharma (Guangzhou) constructed a vector for a recombinant novel coronavirus infection (COVID-19) trivalent (XBB+BA.5+delta) protein vaccine (Sf9 cells) and produced a highly pure and high quality trivalent vaccine for human use. produced a recombinant protein vaccine. Subunit vaccine antigens have been precisely designed based on the structures of the target S-RBD and HR proteins of COVID-19 subvariants XBB and BA.5 and can self-assemble into stable trimeric protein particles. increase.Studies have shown that this vaccine is effective against Omicron XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.5, BF.7, BQ.1, BA.2.75, and multiple subtypes prevalent both domestically and internationally. Shown to be a broad-spectrum COVID-19 vaccine against mutant strains[1].

About WestVac Biopharma

WestVac Biopharma Co., Ltd. is an innovative biopharmaceutical company with an annual vaccine production capacity of 1.1 billion doses, integrating vaccine R&D, production and marketing systems. WestVac Biopharma has been successfully selected for the 2021-2023 list of Unicorn Companies.of December 2022Coviccine® has been approved for emergency use by national authorities and is on vaccine procurement lists in the tender processes of more than 20 states in India. China.




View original content and download multimedia.https://www.prnewswire.com/news-releases/the-first-of-its-kind-in-the-world-the-recombinant-multivalent-covid-19-protein-vaccine-against-xbb-variants- by-westvac-biopharmawest-china-medical-center-sichuan-university-has-been-approved-for-clinical-trials-by-the-national-301828543.html

Source: WestVac BioPharma Co., Ltd.



View original content and download multimedia. http://www.newswire.ca/en/releases/archive/May2023/18/c5470.html

Leave a Reply

Your email address will not be published. Required fields are marked *

Skip to content